1. In Vivo
  2. >>Market Intelligence

IO Driving Surge In Number, Complexity Of Cancer Trials

 
• By John Hodgson

Nearly half of all late-stage cancer trials that started in 2015 had an antibody component, and 2016 brings the first full survival data from pivotal multi-checkpoint antibody trials. We document the immuno-oncology surge in data.

Research and development in oncology continues to expand rapidly. Some 5,906 clinical trials in cancer started between 2010 and 2015, according to Citeline's Trialtrove. (See Exhibit 1.) While the number of later-stage trials has remained relatively constant since 2012, the number of Phase I trials starting has tripled – from 120 in 2012 to over 380 in 2015 – concurrent with the influx of capital into the biotech sector.

SOURCE: Trialtrove

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

J&J Challenges Medtronic At The Top Of Medtech Rankings

 
• By Ashley Yeo

Medtronic held its grip on first place in the 2024 global medical device and diagnostics rankings after losing it two years ago to Abbott, which is now in third place behind fast-rising, acquisitive Johnson & Johnson MedTech.

How Rapport Transferred A Decade Of Big Pharma Neuroscience Expertise To Biotech

 
• By David Wild

Rapport Therapeutics CEO discusses the company's novel approach to AMPA modulation and why strategic externalization from J&J is accelerating neuroscience innovation.

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Podcast: Astellas SVP On Doubling Down On Gene Therapy Despite Industry Headwinds

 
• By David Wild

Richard Wilson, SVP and primary focus lead for genetic regulation at Astellas, talks with In Vivo about the company's commitment to AAV as a gene therapy delivery vehicle, recent company investments and the regulatory environment under Trump's FDA.

More from In Vivo

Does ReproNovo’s $65m Raise Signal An Oasis In The Fertility Investment Desert?

 
• By Jo Shorthouse

ReproNovo's $65m Series A targets the $1.5bn male infertility market with the first potential oral therapy. Its first-in-class approach to underserved conditions like adenomyosis positions it as an attractive acquisition target in fertility's concentrated market.

Moderna Veteran Launches Icelandic mRNA Firm Despite US Retreat

 
• By David Wild

Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By David Wild

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.